UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 294

Sortiert nach

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Clinical cancer research, 2020-06, Vol.26 (12), p.2838-2848

2020

Volltextzugriff (PDF)

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

The oncologist (Dayton, Ohio), 2017-09, Vol.22 (9), p.1039-1048

2017

Volltextzugriff (PDF)

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline

Journal of clinical oncology, 2017-06, Vol.35 (18), p.2062-2081

2017

Volltextzugriff (PDF)

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update

Journal of clinical oncology, 2017-12, Vol.35 (35), p.3978-3986

2017

Volltextzugriff (PDF)

Lapatinib: Current Status and Future Directions in Breast Cancer

The oncologist (Dayton, Ohio), 2006-11, Vol.11 (10), p.1047-1057

2006

Volltextzugriff (PDF)

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience

Journal of clinical oncology, 2015-02, Vol.33 (4), p.340-348

2015

Volltextzugriff (PDF)

American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3816-3824

2011

Volltextzugriff (PDF)

Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.622-630

2015

Volltextzugriff (PDF)

Qualitative study of Oncology Clinicians’ Perceptions of Barriers to Offering Clinical Trials to Underserved Populations

Cancer control, 2023-06, Vol.30, p.10732748231187829-10732748231187829

2023

Volltextzugriff (PDF)

Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

BMC cancer, 2020-04, Vol.20 (1), p.347-347, Article 347

2020

Volltextzugriff (PDF)

Decision Making about Surgery for Early-Stage Breast Cancer

Journal of the American College of Surgeons, 2012-01, Vol.214 (1), p.1-10

2012

Volltextzugriff (PDF)

Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study

Breast (Edinburgh), 2023-02, Vol.67, p.89-93

2023

Volltextzugriff (PDF)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.39-39, Article 39

2019

Volltextzugriff (PDF)

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer

NPJ breast cancer, 2023-04, Vol.9 (1), p.29-29, Article 29

2023

Volltextzugriff (PDF)

Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches

Clinical cancer research, 2006-08, Vol.12 (16), p.4790-4793

2006

Volltextzugriff (PDF)

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer

JAMA oncology, 2016-01, Vol.2 (1), p.29

2016

Volltextzugriff (PDF)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

NPJ breast cancer, 2021-08, Vol.7 (1), p.103-8, Article 103

2021

Volltextzugriff (PDF)

Correlation Between Financial Relationships With Commercial Interests and Research Prominence at an Oncology Meeting

Journal of clinical oncology, 2013-07, Vol.31 (21), p.2678-2684

2013

Volltextzugriff (PDF)

Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer

Radiation oncology (London, England), 2020-08, Vol.15 (1), p.1-7, Article 198

2020

Volltextzugriff (PDF)

Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery

BMC medical informatics and decision making, 2012-06, Vol.12 (1), p.51-51, Article 51

2012

Volltextzugriff (PDF)

Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene

The oncologist (Dayton, Ohio), 2015-06, Vol.20 (6), p.571-571

Moy, Beverly

2015

Volltextzugriff (PDF)

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline

JCO global oncology, 2024-01, Vol.10 (10), p.e2300285-e2300285

2024

Volltextzugriff (PDF)

Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea

Journal of clinical oncology, 2010-06, Vol.28 (18), p.2982-2988

2010

Volltextzugriff (PDF)

1 – 25 von 294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(288)
Mit Volltextzugriff
(266)

Publikationsform

Artikel
(293)
Berichte
(1)

Sprache

Englisch
(294)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(158)
Life Sciences & Biomedicine
(156)
Humans
(125)
Oncology
(121)
Female
(108)
Breast Cancer
(54)
Breast Neoplasms - Drug Therapy
(51)
Middle Aged
(50)
Adult
(37)
Aged
(35)
Breast Neoplasms - Pathology
(34)
Cancer
(25)
Patients
(25)
Biological And Medical Sciences
(24)
Male
(24)
Medical Sciences
(23)
Chemotherapy, Adjuvant
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(20)
Treatment Outcome
(20)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update

Lapatinib: Current Status and Future Directions in Breast Cancer

Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience

American Society of Clinical Oncology Policy Statement: Opportunities in the Patient Protection and Affordable Care Act to Reduce Cancer Care Disparities

Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

Qualitative study of Oncology Clinicians’ Perceptions of Barriers to Offering Clinical Trials to Underserved Populations

Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

Decision Making about Surgery for Early-Stage Breast Cancer

Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer

Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer

Correlation Between Financial Relationships With Commercial Interests and Research Prominence at an Oncology Meeting

Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer

Measuring decision quality: psychometric evaluation of a new instrument for breast cancer surgery

Clinical Trials, Disparities, and Financial Burden: It's Time to Intervene

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline

Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2/neu–Overexpressed/Amplified Breast Cancer Is Not Feasible Because of Excessive Diarrhea

Suchergebnisse filtern